2.84

0.35% 0.010

OncoCyte Corporation (OCX)

Overview News Price History Discussions Forecast Stock Split

OncoCyte Corporation stock is traded at $2.84, with a volume of 8,001. It is up +0.35% in the last 24 hours and down -23.24% over the past month. OncoCyte Corporation focuses on the development and commercialization of novel and non-invasive blood and urine (liquid biopsy) diagnostic tests for the early detection of cancer. The company is developing diagnostic tests using genetic and protein markers expressed in various types of cancer. It develops diagnostic tests based on liquid biopsies using blood or urine samples for detecting lung, bladder, and breast cancer. The company was founded in 2009 and is based in Alameda, California. OncoCyte Corporation is a subsidiary of BioTime, Inc.

Previous Close:

$2.83

Open:

$2.8499

24h Volume:

8,001

Relative Volume:

0.10

Market Cap:

$81.36M

Revenue:

$709.00K

Net Income/Loss:

$-43.14M

P/E Ratio:

-0.6256

EPS:

-4.54

Net Cash Flow:

$-20.35M

1W Performance:

-2.07%

1M Performance:

-23.24%

6M Performance:

-8.97%

1Y Performance:

+9.65%

1-Day Range:

$2.76

$2.8499

1-Week Range:

$2.76

$3.075

52-Week Range:

$1.922

$4.75

OncoCyte Corporation Stock (OCX) Company Profile

Name

OncoCyte Corporation

Sector

Healthcare (1151)

Industry

Biotechnology (660)

Phone

510-775-0515

Address

1010 Atlantic Avenue, Suite 102, Alameda, CA

Employee

Twitter

@OncocyteCorp

Next Earnings Date

2024-11-07

Latest SEC Filings

OCX's Discussions on Twitter

Compare OCX with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
OCX OncoCyte Corporation	2.84	81.36M	709.00K	-43.14M	-20.35M	-4.54
VRTX Vertex Pharmaceuticals Inc	489.10	127.47B	11.02B	-535.60M	-978.00M	-2.20
REGN Regeneron Pharmaceuticals Inc	563.16	62.43B	14.20B	4.41B	3.54B	38.28
ARGX Argen X Se Adr	596.20	37.03B	2.19B	833.04M	-1.28B	12.71
ALNY Alnylam Pharmaceuticals Inc	234.56	31.06B	2.25B	-278.16M	-42.59M	-2.17
ONC Beigene Ltd Adr	230.98	26.16B	3.81B	-644.79M	-669.77M	-6.24

OncoCyte Corporation Stock (OCX) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Mar-28-25	Initiated	Lake Street	Buy
May-24-22	Downgrade	Stephens	Overweight → Equal-Weight
Mar-14-22	Downgrade	KeyBanc Capital Markets	Overweight → Sector Weight
Jan-07-22	Initiated	Stephens	Overweight
Jan-06-22	Resumed	Piper Sandler	Overweight
Mar-17-21	Resumed	Needham	Buy
Jan-07-21	Upgrade	The Benchmark Company	Speculative Buy → Buy
Dec-16-20	Upgrade	Piper Sandler	Neutral → Overweight
Nov-30-20	Initiated	BTIG Research	Buy
Nov-10-20	Initiated	KeyBanc Capital Markets	Overweight
Jul-30-20	Reiterated	The Benchmark Company	Speculative Buy
Jul-01-20	Downgrade	Piper Sandler	Overweight → Neutral
Jun-30-20	Downgrade	Chardan Capital Markets	Buy → Neutral
Jun-02-20	Initiated	Needham	Buy
Feb-13-19	Initiated	Piper Jaffray	Overweight
Jan-29-19	Upgrade	Janney	Neutral → Buy
Dec-19-18	Resumed	Lake Street	Buy

View All

OncoCyte Corporation Stock (OCX) Latest News

Apr 17, 2025

Oncocyte appoints new independent accounting firm - Investing.com

Apr 17, 2025

Oncocyte Appoints Dr. Paul Billings as Consulting Chief Medical Officer - The Globe and Mail

Apr 17, 2025

Apr 08, 2025

BioTime Provides Business Update Including Information on AgeX, OncoCyte and Asterias - MarketScreener

Apr 08, 2025

Apr 07, 2025

OncoCyte (OCX) Upgraded to Buy: What Does It Mean for the Stock? - Yahoo Finance

Apr 07, 2025

OncoCyte (NASDAQ:OCX) Coverage Initiated by Analysts at StockNews.com - Defense World

Apr 07, 2025

Apr 04, 2025

OncoCyte Co. (NASDAQ:OCX) Sees Large Increase in Short Interest - Defense World

Apr 04, 2025

Apr 02, 2025

Oncocyte to Participate in 24th Annual Needham Virtual Healthcare Conference - TradingView

Apr 02, 2025

Oncocyte Unveils Game-Changing Transplant Diagnostic Technology at Major Healthcare Conference - Stock Titan

Apr 02, 2025

Apr 01, 2025

Lake Street starts OncoCyte coverage with Buy, $5 target By Investing.com - Investing.com Canada

Mar 28, 2025

OncoCyte a new buy at Lake Street on transplant rejection testing - MSN

Mar 28, 2025

OncoCyte’s Strategic Positioning and Growth Potential in Transplant Rejection Testing - TipRanks

Mar 28, 2025

OncoCyte initiated with a Buy at Lake Street - TipRanks

Mar 28, 2025

Lake Street Initiates Coverage on OncoCyte (OCX) with Buy Rating - GuruFocus

Mar 28, 2025

Lake Street starts OncoCyte coverage with Buy, $5 target - Investing.com India

Mar 28, 2025

Mar 26, 2025

OncoCyte (NASDAQ:OCX) Receives “Equal Weight” Rating from Stephens - Defense World

Mar 26, 2025

OncoCyte (NASDAQ:OCX) Given Buy Rating at Needham & Company LLC - Defense World

Mar 26, 2025

Mar 25, 2025

OncoCyte Corp’s Positive Earnings Call Highlights Growth - TipRanks

Mar 25, 2025

OncoCyte Corp (OCX) Q4 2024 Earnings Call Highlights: Strategic Partnerships and Regulatory ... - Yahoo

Mar 25, 2025

Earnings call transcript: OncoCyte’s Q4 2024 revenue grows, strategic advances - Investing.com Australia

Mar 25, 2025

Needham maintains Buy on OncoCyte, steady $4.25 target - Investing.com India

Mar 25, 2025

Oncocyte reports progress in organ transplant diagnostics - Investing.com India

Mar 24, 2025

OncoCyte: Q4 Earnings Snapshot -March 24, 2025 at 04:29 pm EDT - Marketscreener.com

Mar 24, 2025

Oncocyte Reports Successful 2024; Sets Stage for 2025 Catalysts - GlobeNewswire

Mar 24, 2025

Mar 22, 2025

Oncocyte secures $29.1 million to advance FDA assay - MSN

Mar 22, 2025

Mar 21, 2025

OncoCyte Corp expected to post a loss of 43 cents a shareEarnings Preview - TradingView

Mar 21, 2025

Mar 20, 2025

Oncocyte Corp Files For Common Stock Offering Of Up To $25.0 MlnSEC Filing - Reuters

Mar 20, 2025

Mar 19, 2025

Oncocyte corp investor Patrick Smith buys $1,839 in shares - MSN

Mar 19, 2025

Mar 18, 2025

Oncocyte to Release Fourth Quarter 2024 Results on March 24, 2025 - The Manila Times

Mar 18, 2025

Oncocyte Sets Key Q4 Earnings Webinar: Live Management Discussion Coming March 24 - Stock Titan

Mar 18, 2025

Mar 14, 2025